Skip to main content

Table 2 IC50 of BTZ-resistant cells to DSF/Cu2+, CFZ and MG-132

From: Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

  BTZ CFZ MG-132 DSF/Cu2+
  IC50 (nM) Fold IC50 (nM) Fold IC50 (nM) Fold IC50 (nM) Fold
CMY 2.9 ± 1.2   1.6 ± 0.4   210 ± 92   68 ± 14  
CMY BR100 175 ± 59 60.4 44.7 ± 2.6 25.2 2345 ± 192 11.2 82 ± 15 1.2
CMY BR200 206 ± 40 71.0 55.5 ± 8.4 31.4 2540 ± 380 12.1 97 ± 27 1.4
CMK 4.3 ± 0.6   4 ± 1.6   303 ± 63   115 ± 30  
CMK BR100 142 ± 46 33.0 73.7 ± 8 16.7 3512 ± 689 11.6 109 ± 15 0.95
  1. IC50 values are presented as mean ± standard deviation and expressed as fold difference compared to parent cell line. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, CFZ carfilzomib, DSF disulfiram